Actively Recruiting
Contribution to Disease Diagnosis and Prognosis Based on the Fusion of Expert Knowledge, Nuclear Medicine Imaging and Artificial Intelligence (AI) Tools
Led by Centre Hospitalier Universitaire de Besancon · Updated on 2024-02-07
1
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire de Besancon
Lead Sponsor
F
Franche-Comté Electronique Mécanique Thermique et Optique - Sciences et Technologies, UMR 6174
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the use of artificial intelligence (AI) algorithms to improve the detection and localization of parathyroid adenomas in patients undergoing parathyroid scans. The study aims to develop programs that automatically subtract planar and tomographic parathyroid images to assist doctors in diagnosing hyperparathyroidism more efficiently. This observational study is conducted using existing imaging data collected from standard diagnostic procedures. The study involves creating an AI-based diagnostic assistance program and an automatic image subtraction tool for double-isotope parathyroid images. These tools will be developed using data from parathyroid scans performed with a dual-isotope protocol involving iodine 123 and technetium 99m, including planar, pinhole, low energy high resolution (LEHR), and SPECT/CT imaging. The imaging data used are collected retrospectively and prospectively without requiring additional examinations. Participants' medical records and imaging data will be reviewed without any extra procedures. Researchers will measure the success of the AI diagnostic program development over an average of four years and the image subtraction program over two years. The study evaluates the agreement between diagnoses made by nuclear physicians using current methods versus the new AI-assisted method. No extra patient visits or treatments are involved, and data use depends on the patient's consent for research purposes.
CONDITIONS
Brief Title
NUclear MEdicine DIagnostic and Artificial Intelligence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women over 18 years of age who underwent dual-isotope parathyroid scintigraphy.
- No refusal to use data for research purposes.
- Retrospective data collected after April 13, 2022, and prospective data.
You will not qualify if you...
- Patient refusal to use data for research purposes.
- Patients who did not undergo the standard acquisition protocol involving iodine 123 injection followed by technetium 99m three hours later, with LEHR, pinhole, and SPECT/CT imaging.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or retrospective data review)
Duration - Up to 4 years
Participants who have undergone routine dual-isotope parathyroid scintigraphy are included with no additional imaging required. Existing imaging data are used for developing and validating the artificial intelligence diagnostic assistance program.
No additional visits; data collection occurs from existing medical records and imaging
Trial Site Locations
Total: 1 location
1
CHU Besancon
Besançon, France, 25030
Actively Recruiting
Research Team
L
Laurent COMAS
L
Laurent COMAS
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here